Leucine-rich repeat-containing protein 59 mediates nuclear import of cancerous inhibitor of PP2A in prostate cancer cells
作者： Rajash Pallai , Aishwarya Bhaskar , Natalie Barnett-Bernodat , Christina Gallo-Ebert , Michelle Pusey
DOI: 10.1007/S13277-015-3326-1
关键词:
摘要: Using yeast two-hybrid analysis, we identified several novel protein interactions for the oncoprotein Cancerous Inhibitor of PP2A (CIP2A) and confirmed a subset these in human cancer cell lines. Analysis interaction prostate carcinoma cells between CIP2A leucine-rich repeat-containing 59 (LRRC59) suggests that is translocated into nucleus at G2/M through its association with LRRC59. Recent work by others has demonstrated nuclear disrupts mitotic checkpoints, which promotes deregulation cycle increases cancerous phenotypes. Thus, provide therapeutic mechanism inhibiting function via targeting CIP2A-LRRC59 interaction.
springer.com
sci-hub.se 参考文章(54)
Dirk Fey, David R Croucher, Walter Kolch, Boris N Kholodenko, None, Crosstalk and Signaling Switches in Mitogen-Activated Protein Kinase Cascades Frontiers in Physiology. ,vol. 3, pp. 355- 355 ,(2012) , 10.3389/FPHYS.2012.00355
G P Shouse, Y Nobumori, M J Panowicz, X Liu, ATM-mediated phosphorylation activates the tumor-suppressive function of B56γ–PP2A Oncogene. ,vol. 30, pp. 3755- 3765 ,(2011) , 10.1038/ONC.2011.95
Yan Zhen, Vigdis Sørensen, Camilla S. Skjerpen, Ellen M. Haugsten, Yixin Jin, Sebastien Wälchli, Sjur Olsnes, Antoni Wiedlocha, Nuclear import of exogenous FGF1 requires the ER-protein LRRC59 and the importins Kpnα1 and Kpnβ1. Traffic. ,vol. 13, pp. 650- 664 ,(2012) , 10.1111/J.1600-0854.2012.01341.X
Pradip De, Jennifer Carlson, Brian Leyland-Jones, Nandini Dey, Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): an oncoprotein with many hands. Oncotarget. ,vol. 5, pp. 4581- 4602 ,(2014) , 10.18632/ONCOTARGET.2127
Jennifer B. Jackson, David C. Pallas, Circumventing Cellular Control of PP2A by Methylation Promotes Transformation in an Akt-Dependent Manner Neoplasia. ,vol. 14, pp. 585- 599 ,(2012) , 10.1593/NEO.12768
Steven Fletcher, Andrew Hamilton, Protein-protein interaction inhibitors: small molecules from screening techniques. Current Topics in Medicinal Chemistry. ,vol. 7, pp. 922- 927 ,(2007) , 10.2174/156802607780906735
Joseph Katz, Andrew Jakymiw, Monet K. Ducksworth, Carol M. Stewart, Indraneel Bhattacharyya, Seunghee Cha, Edward K.L. Chan, CIP2A expression and localization in oral carcinoma and dysplasia. Cancer Biology & Therapy. ,vol. 10, pp. 694- 699 ,(2010) , 10.4161/CBT.10.7.12895
Hui-Chuan Yu, Hui-Ju Chen, Ya-Ling Chang, Chun-Yu Liu, Chung-Wai Shiau, Ann-Lii Cheng, Kuen-Feng Chen, Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma Biochemical Pharmacology. ,vol. 85, pp. 356- 366 ,(2013) , 10.1016/J.BCP.2012.11.009
Lisa P. Huang, Diana Savoly, Abraham A. Sidi, Martin E. Adelson, Eli Mordechai, Jason P. Trama, CIP2A protein expression in high-grade, high-stage bladder cancer Cancer Medicine. ,vol. 1, pp. 76- 81 ,(2012) , 10.1002/CAM4.15
Claire Letourneux, Géraldine Rocher, Françoise Porteu, B56‐containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX‐1 and ERK The EMBO Journal. ,vol. 25, pp. 727- 738 ,(2006) , 10.1038/SJ.EMBOJ.7600980